Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Tommie Reerink maintains a Sell rating on Atara Biotherapeutics (NASDAQ:ATRA) and lowers the price target from $12.5 to $11.
July 17, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs analyst Tommie Reerink maintains a Sell rating on Atara Biotherapeutics and lowers the price target from $12.5 to $11.
The Sell rating and lowered price target from a major financial institution like Goldman Sachs is likely to negatively impact investor sentiment and the stock price of Atara Biotherapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100